Immunotherapy and prostate cancer

Joseph M. Kaminski, James B. Summers, Matthew B. Ward, Mark R. Huber, Boris Minev

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Prostate cancer is the second leading cause of cancer death in the US, largely because of the limitations of our current therapeutic options, especially once the cancer has metastasized. Investigators have long sought new therapeutic modalities such as angiogenesis inhibitors, vaccines, and gene therapy, among others. It appear's that a combination approach will be required to cure the majority of malignancies. Immunotherapy for prostate cancer appears feasible and a likely therapeutic modality in the armamentarium. Unfortunately, further research in basic immunology and the interaction of the immune system with other forms of therapy is needed. Many obstacles exist in immunotherapy, including vector design, tumouricidal specificity, and tumor evasion, which will have to be overcome in order to realize the maximum therapeutic benefit from this treatment modality.

Original languageEnglish (US)
Pages (from-to)199-209
Number of pages11
JournalCancer Treatment Reviews
Volume29
Issue number3
DOIs
StatePublished - Jun 2003

Fingerprint

Immunotherapy
Prostatic Neoplasms
Neoplasms
Therapeutics
Active Immunotherapy
Angiogenesis Inhibitors
Allergy and Immunology
Genetic Therapy
Cause of Death
Immune System
Research Personnel
Research

Keywords

  • Cancer
  • Gene therapy
  • Immunotherapy
  • Prostate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Kaminski, J. M., Summers, J. B., Ward, M. B., Huber, M. R., & Minev, B. (2003). Immunotherapy and prostate cancer. Cancer Treatment Reviews, 29(3), 199-209. https://doi.org/10.1016/S0305-7372(03)00005-7

Immunotherapy and prostate cancer. / Kaminski, Joseph M.; Summers, James B.; Ward, Matthew B.; Huber, Mark R.; Minev, Boris.

In: Cancer Treatment Reviews, Vol. 29, No. 3, 06.2003, p. 199-209.

Research output: Contribution to journalReview article

Kaminski, JM, Summers, JB, Ward, MB, Huber, MR & Minev, B 2003, 'Immunotherapy and prostate cancer', Cancer Treatment Reviews, vol. 29, no. 3, pp. 199-209. https://doi.org/10.1016/S0305-7372(03)00005-7
Kaminski JM, Summers JB, Ward MB, Huber MR, Minev B. Immunotherapy and prostate cancer. Cancer Treatment Reviews. 2003 Jun;29(3):199-209. https://doi.org/10.1016/S0305-7372(03)00005-7
Kaminski, Joseph M. ; Summers, James B. ; Ward, Matthew B. ; Huber, Mark R. ; Minev, Boris. / Immunotherapy and prostate cancer. In: Cancer Treatment Reviews. 2003 ; Vol. 29, No. 3. pp. 199-209.
@article{09779e57834a467583debedf0a4133ab,
title = "Immunotherapy and prostate cancer",
abstract = "Prostate cancer is the second leading cause of cancer death in the US, largely because of the limitations of our current therapeutic options, especially once the cancer has metastasized. Investigators have long sought new therapeutic modalities such as angiogenesis inhibitors, vaccines, and gene therapy, among others. It appear's that a combination approach will be required to cure the majority of malignancies. Immunotherapy for prostate cancer appears feasible and a likely therapeutic modality in the armamentarium. Unfortunately, further research in basic immunology and the interaction of the immune system with other forms of therapy is needed. Many obstacles exist in immunotherapy, including vector design, tumouricidal specificity, and tumor evasion, which will have to be overcome in order to realize the maximum therapeutic benefit from this treatment modality.",
keywords = "Cancer, Gene therapy, Immunotherapy, Prostate",
author = "Kaminski, {Joseph M.} and Summers, {James B.} and Ward, {Matthew B.} and Huber, {Mark R.} and Boris Minev",
year = "2003",
month = "6",
doi = "10.1016/S0305-7372(03)00005-7",
language = "English (US)",
volume = "29",
pages = "199--209",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Immunotherapy and prostate cancer

AU - Kaminski, Joseph M.

AU - Summers, James B.

AU - Ward, Matthew B.

AU - Huber, Mark R.

AU - Minev, Boris

PY - 2003/6

Y1 - 2003/6

N2 - Prostate cancer is the second leading cause of cancer death in the US, largely because of the limitations of our current therapeutic options, especially once the cancer has metastasized. Investigators have long sought new therapeutic modalities such as angiogenesis inhibitors, vaccines, and gene therapy, among others. It appear's that a combination approach will be required to cure the majority of malignancies. Immunotherapy for prostate cancer appears feasible and a likely therapeutic modality in the armamentarium. Unfortunately, further research in basic immunology and the interaction of the immune system with other forms of therapy is needed. Many obstacles exist in immunotherapy, including vector design, tumouricidal specificity, and tumor evasion, which will have to be overcome in order to realize the maximum therapeutic benefit from this treatment modality.

AB - Prostate cancer is the second leading cause of cancer death in the US, largely because of the limitations of our current therapeutic options, especially once the cancer has metastasized. Investigators have long sought new therapeutic modalities such as angiogenesis inhibitors, vaccines, and gene therapy, among others. It appear's that a combination approach will be required to cure the majority of malignancies. Immunotherapy for prostate cancer appears feasible and a likely therapeutic modality in the armamentarium. Unfortunately, further research in basic immunology and the interaction of the immune system with other forms of therapy is needed. Many obstacles exist in immunotherapy, including vector design, tumouricidal specificity, and tumor evasion, which will have to be overcome in order to realize the maximum therapeutic benefit from this treatment modality.

KW - Cancer

KW - Gene therapy

KW - Immunotherapy

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=0038819624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038819624&partnerID=8YFLogxK

U2 - 10.1016/S0305-7372(03)00005-7

DO - 10.1016/S0305-7372(03)00005-7

M3 - Review article

C2 - 12787714

AN - SCOPUS:0038819624

VL - 29

SP - 199

EP - 209

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -